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Abstract
COVID-19 is an acute respiratory infection accompanied by pneumonia caused by severe acute respiratory syndrome coro-
navirus 2 (SARS-CoV-2), which has affected millions of people globally. To date, there are no highly efficient therapies for 
this infection. Probiotic bacteria can interact with the gut microbiome to strengthen the immune system, enhance immune 
responses, and induce appropriate immune signaling pathways. Several probiotics have been confirmed to reduce the duration 
of bacterial or viral infections. Immune fitness may be one of the approaches by which protection against viral infections can 
be reinforced. In general, prevention is more efficient than therapy in fighting viral infections. Thus, probiotics have emerged 
as suitable candidates for controlling these infections. During the COVID-19 pandemic, any approach with the capacity to 
induce mucosal and systemic reactions could potentially be useful. Here, we summarize findings regarding the effectiveness 
of various probiotics for preventing virus-induced respiratory infectious diseases, especially those that could be employed 
for COVID-19 patients. However, the benefits of probiotics are strain-specific, and it is necessary to identify the bacterial 
strains that are scientifically established to be beneficial.
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Introduction
Respiratory infections (RIs) cause high morbidity and 
mortality globally. The viruses most frequently responsible 
for these infections include influenza viruses (IVs), coro-
naviruses, respiratory syncytial virus (RSV), parainfluenza 
viruses (PIVs), adenoviruses, and rhinoviruses (RVs) [14, 
142]. The severity of viral respiratory infections varies 
widely, and severe disorders mostly occur in children and 
older adults [184]. Fatalities are often observed following 
a viral infection, which can be exacerbated by underlying 
conditions or coinfection of the paranasal sinuses, mid-
dle ear, or lungs [184]. Most importantly, an outbreak of 
SARS-CoV-2, which causes the disease COVID-19, was 
initially reported in China in December 2019 and quickly 
spread worldwide [124, 126, 127, 170]. By December 16, 
2020, the virus had caused 71,581,532 confirmed cases 
and 1,618,374 deaths worldwide [137]. Currently, there 
are no highly effective drugs for treatment of COVID-19 
[57, 124, 125, 128]. Consequently, it is crucial to discover 
alternative and safe approaches to reduce the risk of this 
infection.
Currently, some probiotics have been reported to pre-
vent and alleviate bacterial and viral infections (VIs) 
[84]. Most of our findings regarding the reinforcement of 
immune reactions by probiotics have been from in vivo 
investigations. For instance, intranasal inoculation of mice 
with Lactobacillus reuteri and Lactobacillus plantarum 
has shown protective effects against lethal viral pneumo-
nia [84]. The expected outcome of probiotic treatment in 
human investigations includes alleviation of diarrhea in 
infants and reduction of the severity of milk allergy in 
children and irritable bowel syndrome [44]. Probiotics 
likely affect mucosae by adjusting the microbiota, hin-
dering the growth of pathogens, and increasing local and 
systemic immune reactions [68].
Regarding the advantages of probiotics in viral dis-
eases, particular probiotic strains have been found to be 
efficient in reducing the duration and severity of gastroen-
teritis caused by rotaviruses [56]. More importantly, there 
is increasing evidence that probiotics are beneficial in the 
control of viral respiratory infections [97, 178]. Recent 
immunological studies have provided a better understand-
ing of the role of innate immune responses and subsequent 
adaptive immune responses in the recognition and eradi-
cation of viral infections. For instance, it has been found 
that the production of type 1 interferons (IFNs) mainly 
mediates the control of viral infection, immune pathology, 
and the management of inflammatory cytokines via Toll-
like receptors and retinoic-acid-inducible gene I [129, 158, 
180]. Several studies have elucidated the immunostimula-
tory effects of probiotic bacteria and have described their 
capability to prevent VIs [3, 13, 100]. Accordingly, pro-
biotic administration may be effective in reducing and/
or blocking SARS-CoV-2 infection, which has caused 
an enormous health and economic burden. This review 
describes current preventive and curative trial studies 
based on the use of probiotics against viral respiratory 
tract infections. We then outline the possible application 
of probiotic bacteria as a prophylactic approach against 
COVID-19.
Viral respiratory infections
The respiratory tract (upper or lower) is affected by many 
VIs [34, 169]. These infections are clinically categorized 
based on the type of infection (e.g., bronchiolitis, common 
cold, pneumonia), and not based on the type of causative 
agent (influenza) [34, 169]. Although particular viral patho-
gens generally cause characteristic clinical outcomes (e.g., 
respiratory syncytial virus causes bronchiolitis, while rhino-
viruses cause the common cold), each pathogen can cause 
viral respiratory syndromes [8, 146]. The severity of viral 
respiratory disorders varies widely, and severe disorders are 
more likely to occur in children and older adults [31, 175, 
186]. In most cases, respiratory viral infections are limited 
to the upper parts of the respiratory tract, where they induce 
relatively mild symptoms such as runny nose and sneezing 
[145]. Nevertheless, in susceptible individuals such as the 
elderly and newborns, infection can affect the lower respira-
tory airways, leading to wheezing, bronchiolitis, shortness 
of breath, and pneumonia [31, 175, 186]. Common respira-
tory viral pathogens include RSV, metapneumovirus, PIVs, 
bocaviruses, adenoviruses, IVs, RVs, and coronaviruses [14, 
85].
Recent developments in virology have led to the develop-
ment of standardized diagnostic techniques and the discov-
ery of novel respiratory viruses such as influenza virus A 
(IVA), influenza virus B (IVB) and novel human coronavi-
ruses (HCoVs) with the ability to cause a pandemic [214]. In 
contrast to the regular seasonal outbreaks of influenza, pan-
demics occur irregularly. For example, the so-called Spanish 
influenza pandemic in 1918 was the worst in recorded history 
and was responsible for about 50–100 million deaths [161, 
179]. The influenza pandemic in 2009 was caused by IVA 
(H1N1) and is believed to have caused 100,000 to 400,000 
deaths [35]. Coronaviruses are a large family of viruses with 
a broad range of hosts (humans and animals). Sometimes, an 
animal coronavirus can shift its host specificity, allowing it 
to infect humans [41, 199]. Several well-known human coro-
naviruses, including 229E, NL63, OC43, and KHU1, have 
emerged recently and induce mild-to-moderate RIs such as 
the common cold [212]. However, SARS-CoV-1 and Middle 
East respiratory syndrome coronavirus (MERS-CoV) can 
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cause critical RIs, and in 2003, the SARS-CoV-1 outbreak 
infected 8098 people, causing 774 deaths, while from 2012 
to 2019, MERS infected 2494 people, causing 858 deaths 
[141]. SARS-CoV-2, which was first discovered in China, 
has caused an ongoing worldwide pandemic and, by October 
1, 2020, this virus was responsible for 33,842,281 confirmed 
cases and 1,010,634 deaths worldwide [137].
Immune reactions and pathogenesis 
of COVID‑19
It has been found that in severe cases of SARS-CoV-2 
disease, the number of naive T helper (Th) lymphocytes 
increases while the number of memory Th lymphocytes and 
 CD28+ T lymphocytes decreases [150, 190]. The balance 
between memory T lymphocytes and naïve T lymphocytes is 
essential for proper host immune reactions [160]. Addition-
ally, decreased numbers of natural killer (NK) cells and B 
lymphocytes have been observed in SARS-CoV-2 infection 
[107, 185]. Another important finding is the documented 
association between inflammatory signs, such as IL-6 pro-
duction, erythrocyte sedimentation, and C-reactive protein 
induction [193]. Although the proportion of  CD4+/CD8+ T 
lymphocytes in COVID-19 patients is usually the same as in 
uninfected subjects, an elevation of this ratio and a decreased 
proportion of  CD8+ T lymphocytes and B lymphocytes have 
been suggested as predictors of poor outcome in follow-up 
[190, 193].
After the virus enters a cell, viral antigens are given to 
antigen-presenting cells (APCs), and this step is crucial 
in antiviral immunity [104]. The histocompatibility com-
plex (MHC or human leukocyte antigen [HLA]) presents 
the viral antigen (antigenic peptide) to specific cytotoxic 
T lymphocytes (CTLs) [104]. Therefore, understanding 
SARS-CoV-2 antigen presentation will help researchers bet-
ter understand COVID-19 pathogenesis [104]. So far, our 
information about SARS-CoV-2 is incomplete, and most 
of our current knowledge is from earlier investigations on 
SARS-CoV-1 and MERS-CoV. MHC I, rather than MHC II, 
is the source of SARS-CoV-1 antigen presentation to CTLs 
[104, 108]. Previous research has shown a correlation of 
HLA polymorphisms such as HLA-B*4601, HLA-B*0703, 
HLA-DR B1*1202, and HLA-Cw*0801, with susceptibility 
to SARS-CoV-1 infection. In contrast, some alleles, such as 
HLA-DR0301, HLA-Cw1502, and HLA-A*0201, have been 
linked to protection against SARS-CoV-1 disease [104]. 
MHC II is correlated with host susceptibility to MERS-CoV 
disease (such as HLA-DRB1*11:01 and HLA-DQB1*02:0) 
[66]. It has also been shown that a mannose-binding lectin 
polymorphism is correlated with an increased risk of SARS-
CoV-1 infection [183]. These investigations provide signifi-
cant insights into for COVID-19 pathogenesis.
Antigen presentation initiates the induction of adaptive 
immunity (humoral and cellular responses via virus-specific 
B and T cells) [104]. As in other acute VIs, typical IgM and 
IgG responses are generated against SARS-CoV-1 [104]. 
The specific IgM produced against SARS-CoV-1 disappears 
at the end of week 12. In contrast, the IgG antibody can 
persist for a longer period, suggesting its potential protec-
tive role. The S and N proteins of SARS-CoV-1 are pri-
mary targets for the production of specific IgGs [40, 101, 
104]. Compared to humoral responses, more studies have 
been conducted on cellular immunity against coronaviruses. 
Recent analysis of the peripheral blood of SARS-CoV-
2-infected subjects has demonstrated reduced numbers of 
 CD4+ and  CD8+ T cells. Similarly, a significant reduction 
in  CD4+ and  CD8+ T cells is correlated with the acute phase 
of SARS-CoV-1 infection [104]. Even in the absence of anti-
gens,  CD4+ and  CD8+ memory T cells can persist for four 
years in some SARS patients, with T cell propagation, DTH 
reactions, and IFN-γ generation [49]. A specific memory T 
cell response to the SARS-CoV-1 S peptide could still be 
observed in 14 out of 23 recovered patients, even six years 
after infection [177]. Regarding MERS-CoV, specific  CD8+ 
T cell responses are responsible for clearing this virus in 
mice [215]. These findings might provide a basis for devel-
oping appropriate therapeutic approaches for treating SARS-
CoV-2 infections.
Potential mechanisms of action of probiotics 
in prevention of respiratory viral infections
Probiotics are live microorganisms that confer a health 
benefit on the host [50]. They commonly affect the innate 
and adaptive immune responses and can reduce the sever-
ity of disease in various disorders, including respiratory 
tract infections [73, 98, 140]. Recently, some probiotics 
were found to exert their immunomodulatory effect through 
their components, such as peptidoglycan, lipoteichoic acid, 
nucleic acid, which stimulates Toll-like receptors, and mura-
myl dipeptide, which stimulates Nod-like receptors [147]. 
Immune modulation occurs through regulatory T cells, type 
3 innate lymphoid cells, and Th17 cells by recognizing the 
probiotic strain or its components and its effect on mucosal 
immunity [58, 84, 143]. The mechanism of action of probiot-
ics in VIs is not entirely appreciated. However, it has been 
suggested that bacterial probiotics might bind to viruses, 
thus hindering viral binding to the host receptor [84]. Over-
all, the following mechanisms have been proposed for the 
effects of probiotics on viral respiratory infections (Fig. 1):
• Direct effect by a trapping strategy
• Activation of the immune reactions by interleukins, NK 
cells, Th1, and IgA production
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• Induction of mucosal protection (gut mucins may attach 
to viruses and restrain viral replication)
• Production of antiviral components such as bacteriocins 
and hydrogen peroxide  (H2O2)
• Induction of low-level nitric oxide (NO) generation by 
host cells and dehydrogenase formation
• Immunomodulation of immune cells (such as mac-
rophages and dendritic cells [DCs])
• Induction of the differentiation of  CD8+ T cells into 
CTLs, which kill infected cells
• Differentiation of  CD4+ T cells into Th1 and Th2 cells 
(and induction of B cells by Th2-cells) [84, 178].
Clinical outcomes of using probiotics 
as a prophylactic approach for viral 
respiratory infections
Lactobacillus and Bifidobacterium are two main genera 
that are commonly used as probiotics [52]. The beneficial 
effects of probiotics on viral infections have been reported 
[97, 178]. A list of probiotic bacteria administered in viral 
respiratory infections is shown in Table 1. In this section, we 
describe some of the promising research findings (Table 2). 
Luoto and colleagues studied early modifications of 
immune responses and gut microbiota following Lactobacil-
lus rhamnosus GG administration to reduce the risk of viral 
respiratory infections in preterm newborns during their first 
year of life [113]. They found a significant reduction in the 
frequency of VRIs, in particular rhinovirus infections, when 
administering specific probiotic metabolites such as galac-
tooligosaccharides and polydextrose. They also observed 
immunomodulatory effects that conferred clinical ben-
efits exceeding those due to interference with viral growth 
[113]. The rationale for the administration of probiotics for 
the prevention of VRIs is based on their capacity to dimin-
ish colonization of respiratory epithelia by pathogens and 
control mucosal resistance via activation of inflammasomes 
and systemic immune reactions [55, 79]. It has been demon-
strated that early treatment with dietary L. rhamnosus GG in 
preterm newborns can have long-lasting effects and decrease 
the risk of VRIs. In separate studies, Kumpu and colleagues 
Fig. 1  The antiviral effects of probiotics during respiratory viral 
infections. MALT, mucosa-associated lymphoid tissue; NK cell, natu-
ral killer cell; CTL, cytotoxic T lymphocyte; Th1, T helper 1; Th2, T 
helper 2; DC, dendritic cell; M cell, microfold cell; IgM, immuno-
globulin M; IgG, immunoglobulin G; IgA, immunoglobulin A; IFNs, 
interferons; IL-1b, interleukin 1 beta; TNF-a, tumour necrosis gactor 
alpha; IL-6, interleukin 6; NO, nitric oxide
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Table 1  Clinical outcome of using probiotic bacterial strains for viral respiratory infections.
Bacterial strain Viral respiratory infection Outcome Reference
Lactobacillus GG (LGG) Respiratory tract infections The study assessed the performance of 
LGG in the restriction of respiratory tract 
diseases in children attending daycare 
centers. Their results indicated that LGG 
treatment could be advised as a valid 
means of reducing the risk of upper 
respiratory tract diseases in children 
attending daycare centers.
[75]
Lactobacillus paracasei N1115 Upper respiratory tract infections (URTI) The investigation was to evaluate whether 
yogurt enriched with a probiotic strain 
could benefit middle-aged and older 
adults suffering from severe URTIs in a 
randomized, blank-controlled, parallel-
group trial. The study results recom-
mended that yogurt with chosen probiotic 
strains such as N1115 may diminish the 
risk of severe upper tract diseases in the 
elderly. The augmentation of T-cell-
mediated immune protection might be 
one of the critical underlying mechanisms 
by which probiotics help to alleviate 
infections.
[149]
Haemophilus influenzae, Streptococcus, 
Corynebacterium, Moraxella, Staphylo-
coccus aureus
Respiratory syncytial virus (RSV) The study assessed whether specific 
nasopharyngeal microbiota are correlated 
with distinct host transcriptomic profiles 
and infection severity in children infected 
with RSV. The study results showed that 
the interplay between RSV and naso-
pharyngeal microbiota might temper host 
immune responses, possibly altering the 
clinical severity of the disease.
[36]
Lactobacillus rhamnosus GG Respiratory tract infections The study hypothesized that early prebiotic 
or probiotic supplementation could 
decrease the risk of virus-associated RTIs 
throughout the first year of life in a cohort 
study on preterm infants. The results 
demonstrated that altering gut microbiota 
with specific prebiotics and probiotics 
might represent a novel and cost-effective 
approach to decreasing the risk of rhino-
virus infections.
[113]
Lactobacillus rhamnosus GG Respiratory illness This study showed that long-term daily use 
of milk containing Lactobacillus rhamno-
sus GG decreased the rate of respiratory 
illnesses in children attending daycare 
centers (those who finished the treatment 
course, and not the whole population).
[90]
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Table 1  (continued)
Bacterial strain Viral respiratory infection Outcome Reference
Lactobacillus rhamnosus GG Respiratory tract infection In this randomized, double-blinded, 
placebo-controlled 28-week intervention, 
nasopharyngeal swab specimens were 
obtained from children suffering from 
respiratory infections who were given 
normal milk (N = 97) or the same milk 
enriched with the probiotic Lactobacil-
lus rhamnosus GG (N = 97). This study 
showed that children taking Lactobacillus 
rhamnosus GG had a shorter time with 
respiratory manifestations than children 
in the control group. However, probiotic 
treatment did not decrease the amount of 
viral shedding or the severity of respira-
tory signs.
[93]
Lactobacillus casei rhamnosus Respiratory tract infection This study examined the treatment and pre-
vention performance of three commercial 
probiotic products on pediatric infectious 
diseases in a double-blind, randomized, 
controlled trial. This investigation showed 
that L. casei could alleviate bacterial, 
viral, and respiratory infections.
[106]
Bifidobacterium lactis subs plactis Bl-04
Lactobacillus acidophilus NCFM
Bifidobacterium animalis subsp. Lactis 
Bi-07
Respiratory tract infection This study aimed to examine the effect 
of supplementation with probiotics on 
respiratory and gastrointestinal disorders 
in healthy working men and women. This 
study indicated that the Bl-04 probiotic 
taken as a nutritional supplement was 
beneficial for decreasing the risk of URTI 
in healthy, physically active adults.
[201]
Lactobacillus gasseri PA 16/8, Bifidobacte-
rium longum SP 07/3, B. bifidum MF 20/5
Common cold This study evaluated the effects of using L. 
gasseri PA 16/8, B. longum SP 07/3, and 
B. bifidum MF 20/5 (5 ×  107) cfu/tablet) 
for at least three months on the severity 
of manifestations and the frequency and 
duration of the common cold. This study 
showed that the intake of probiotic bacte-
ria for at least three months significantly 
decreased the duration by approximately 
two days and diminished the severity of 
manifestations.
[38]
Lactobacillus fermentum (CECT5716) Influenza The co-adjuvant capacity of the oral admin-
istration of the breast-milk-isolated strain 
Lactobacillus fermentum (CECT5716) 
with an anti-influenza vaccine was evalu-
ated. This study demonstrated that oral 
treatment with L. fermentum CECT5716 
potentiates the immunologic responses 
to the anti-influenza vaccine and may 
enhance protection by boosting the 





surveyed the ability of L. rhamnosus GG to decrease the 
incidence and/or signs of viral infection in children [92]. 
They found that the duration of respiratory symptoms was 
notably shorter lower in children who received L. rhamnosus 
GG than in those who did not. However, in their study, L. 
rhamnosus GG treatment did not significantly decrease the 
incidence or symptoms of VRIs in the nasopharynx. This 
could be due to the comparably low dose of diurnal L. rham-
nosus GG  (108 CFU) administered in this trial compared 
with others [92].
Kumpu and colleagues identified several types of res-
piratory viruses in the nasopharynx of infants visiting day-
care centers [92]. Hojsak and colleagues also investigated 
the ability of Lactobacillus GG to restrict gastrointestinal 
and respiratory tract infections (RTIs) in infants who vis-
ited daycare centers [75] and that the daily consumption of 
probiotics significantly decreased the incidence of upper 
RTIs.
In another study by Kumpu and colleagues, the effect of 
long-term daily consumption of milk containing L. rham-
nosus GG was investigated on children with VRIs [91]. 
According to their results, a statistically significant reduc-
tion in respiratory manifestations was observed in the L. 
rhamnosus GG group compared to children in the placebo 
group. Lin and colleagues compared the efficacy of commer-
cial probiotics on the incidence of VRIs in infants [110]. An 
exciting result of their work was that probiotic supplemen-
tation reduced the number of clinical visits, notably among 
those who had frequently been referred to physicians [110]. 
It concomitantly increased the number of infants who did not 
visit a physician during the interference phase, and the use 
of L. rhamnosus decreased VIs by 18% in the interference 
Table 1  (continued)
Bacterial strain Viral respiratory infection Outcome Reference
Lactobacillus casei DN-114 001 Respiratory tract infection The study investigated the ability of a 
dairy product containing the probiotic 
strain Lactobacillus casei DN-114 001 
to protect independently-living elderly 
individuals against widespread infectious 
diseases. The results showed that the 
consumption of the probiotic was cor-
related with a reduced duration of routine 
infectious disorders, particularly URTIs 
such as rhinopharyngitis, compared with 
a control group.
[63]
Lactobacillus bulgaricus OLL1073R-1 Respiratory tract infection This study evaluated whether the con-
sumption of yogurt fermented with 
Lactobacillus delbrueckii ssp. bul-
garicus OLL1073R-1 had a protective 
effect against the common cold. The 
results showed that the consumption of 
yoghurt fermented with L. bulgaricus 
OLL1073R-1 increased natural killer cell 
activity and reduced the risk of catching a 







Influenza This study evaluated whether precise 
bacterial community structures in the 
nasopharynx of children during hospitali-
zation are correlated with various clinical 
consequences of influenza. The results 
showed that the expanded bacterial diver-
sity in the nasopharynx of children was 
considerably correlated with influenza 
severity. Patients with severe influenza 
showed a reduced relative frequency 
of S. aureus and increased abundance 
of Prevotella, Streptobacillus, Porphy-
romonas, Granulicatella, Veillonella, 
Fusobacterium, and Haemophilus in their 
nasopharynx. This suggests the poten-
tial application of microbial signatures 
as prognostic biomarkers of influenza 
outcome.
[96]




















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































group [110]. Probiotics, depending on the strain and spe-
cies, can be potent modulators of the immune system [116, 
117]. Lin and colleagues showed the effect of Lactobacillus 
spp. on antigen-specific IgG and cytokine reactions [110]. 
Specific Lactobacillus strains can induce myeloid DCs to 
activate T cells and induce the production of Th1 cytokines. 
They can therefore be considered potential biotherapeutic 
agents [130]. West and colleagues studied the effects of 
using a single strain, Bifidobacterium lactis subsp. lactis 
Bl-04, as a probiotic or a combination of Lactobacillus aci-
dophilus NCFM and Bifidobacterium animalis subsp. lactis 
Bi-07 on pulmonary and gastrointestinal diseases in healthy 
subjects [202]. They found that daily B. lactis Bl-04 supple-
mentation led to a 27% decline in RTI incidence compared 
to a placebo. In seasonal infections similar to the common 
cold, a delay in disease incidence indicated an affirmative 
clinical advantage from supplementation.
Vrese and colleagues examined whether the consump-
tion of probiotic bacteria for at least three months in win-
ter/spring could affect the severity of signs, the frequency, 
and the duration of the common cold, as well as immune 
reactions in normal adults [39]. They showed that probi-
otic bacteria significantly decreased the average duration of 
infection and lessened the severity of symptoms [39]. These 
results were comparable to those of neuraminidase inhibitors 
(NIs), which, when used during the first 48 h of IV infection, 
decreased the severity of signs and decreased the infection 
duration by one day [39]. In contrast to NIs, probiotics can 
be administered as a part of the diurnal regimen and do not 
impose further costs. The reduced severity and duration of 
cold symptoms may be due to immunostimulatory effects, 
and in response to specific probiotic strains, distinct cell 
lines, such as peripheral blood mononuclear cells, mono-
cytes, DCs, and intestinal cells from human mucosa have 
been shown to secrete pro- or anti-inflammatory cytokines 
and co-stimulatory molecules [15, 24, 71]. According to a 
study by Vrese and colleagues, CTLs, along with  CD8+ T 
cells (suppressor cells), increased significantly throughout 
the initial 14 days of supplementation in a probiotic-treated 
group that was compared to control subjects [39].
Although vaccination against IVs is known to prevent 
severe illnesses, particularly in communities at risk, in some 
cases, vaccine efficacy is low, suggesting the need to develop 
new adjuvant components [122]. Some Lactobacillus strains 
(e.g., Lactobacillus fermentum CECT5716) have been sug-
gested as suitable coadjuvants for increasing antibody 
production after IV vaccination [37]. During IV infection, 
innate immunity forms an early barrier against the virus via 
executive cells, molecules, and agents involved in the restric-
tion of viral spread [105, 176]. In this regard, Olivares and 
colleagues showed that oral administration of L. fermentum 
CECT5716 led to an increase in NK cells 14 days after vac-
cination [134]. Although IgA and IgG provide the crucial 
protective humoral immunity induced by IV infection, these 
authors observed an enhancement of the specific anti-IV IgA 
response in subjects receiving probiotics, but no such effect 
on IgG or IgM levels was observed [134].
Guillemard and colleagues investigated the beneficial 
effect of Lactobacillus casei DN-114 001 for protection of 
older adults against common RIs [64]. In their study, fer-
mented products were shown to decrease the duration of 
common RIs. More importantly, significant reductions were 
observed for all RIs, in particular, rhinopharyngitis. In an 
unblinded trial, elderly individuals immunized against influ-
enza and pneumococcus demonstrated a lower frequency 
of disease, particularly viral respiratory infections, after 
administration of a nutritional complement consisting of L. 
paracasei and additional nutrients such as vitamins [19]. 
The reduced duration of RIs could be correlated with a low-
ered risk of medical complications, because infections with 
human rhinoviruses, the most prevalent cause of RIs, were 
found to be correlated with a high incidence of prolonged 
disease and a lower rate of pulmonary disorders in older 
individuals [70, 188]. For instance, Guillemard and col-
leagues found that consumption of fermented dairy products 
containing L. casei DN-114 001 was linked to a significant 
reduction in the duration of common rhinopharyngitis, pro-
viding evidence that probiotics may have beneficial effects 
on RIs in the elderly [64].
Makino and colleagues assessed whether the consump-
tion of yogurt fermented with Lactobacillus bulgaricus 
OLL1073R-1 improves immunity against RTIs such as the 
common cold and IV infections [119]. Their results showed 
that L. bulgaricus OLL1073R-1 significantly diminished the 
risk of common cold among the elderly. It was previously 
reported that 1073R-1 yogurt and its polysaccharides inten-
sify NK cell activity in mice [118]. NK cells are involved 
in antiviral defense, and low NK cell activity has been 
linked to the development of common cold, pneumonia, 
acute bronchitis, and death in older adults [62, 133]. Hence, 
the effect of 1073R-1 yogurt is mainly associated with the 
immunostimulatory effect of polysaccharides formed by L. 
bulgaricus OLL1073R-1.
Potential role of commensal microbiota 
in protecting the respiratory tract 
against infectious agents
A notable difference in lung microbiota composition has 
been observed between SARS-CoV-2 pneumonia patients 
and healthy subjects, suggesting the occurrence of dysbiosis 
in the lung microbiota of COVID-19 patients [46]. Strepto-
coccus salivarius is a prevailing commensal bacterium in 
the healthy oral and upper respiratory tract [46]. There have 
been several reports on interference by this bacterium with 
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the growth of potential pathogens [46]. Along with other 
oral commensals, S. salivarius is commonly found in the 
lung and is associated with maintenance of good health [46]. 
The lung microbiota of COVID-19 patients is significantly 
modified and enriched in potentially pathogenic bacteria 
[46]. Strain K12 is the best-studied strain of S. salivarius 
[46]. Establishment of an upper respiratory tract (URT) 
infection with strain K12 can significantly decrease the 
occurrence of many viral URT infections, both in children 
and in older adults, possibly owing to its ability to induce 
IFN-γ release and activate NK cells without triggering 
destructive inflammatory responses [16]. Although its effi-
cacy against COVID-19 has never been investigated explic-
itly, its clinical potential as well as its safety profile, which 
can last >20 years following probiotic application, might 
encourage medical doctors to reconsider prescribing it as a 
supplement to help control viral respiratory infections and 
associated pneumonia by enhancing host immune functions.
Probiotic bacteria can inhibit colonization and establish-
ment of infection by viral and bacterial pathogens [22]. For 
example, proteases generated by Staphylococcus epidermidis 
can degrade the biofilm structure of Staphylococcus aureus 
[82, 123, 152, 187]. In this regard, nasal administration of a 
bacterium that belongs to the healthy human microbiota ben-
efits the patient by re-establishing a microbial balance and 
reducing the level of various pathogens in the airways [89].
IFN-λ is a significant immune regulator in various VIs in 
the epithelial layer (mucosa), and stimulation of IFN-λ pro-
duction results in a quick response of immune cells to human 
respiratory viruses [53, 86]. IFN-λ is thought to be involved 
in the initial defense against viral attackers in the host res-
piratory system and plays a crucial role in local antiviral 
innate immunity [53, 86]. Nevertheless, our current knowl-
edge about the modulators that contribute to the production 
of IFN-λ, particularly in natural RVIs, is limited. The human 
mucosal surface is exposed to elements of the external envi-
ronment and is thus sensitive to colonization and invasion 
by numerous pathogens [47]. Mucosal immunity appears to 
have evolved to accommodate the interaction between the 
host and the mucosal microbiome, with protection mediated 
by the microbiome against infections from outside micro-
bial pathogens [74]. Various inhaled microbial pathogens 
encounter immune cells soon after their first contact with 
respiratory mucosa, and the microbial community in the 
nasal passage affects the primary immune reactions directly 
[87]. Understanding the microbiome of human nasal mucosa 
could provide substantial knowledge about the susceptibility 
of the respiratory tract to viral infections and components 
involved in immune reactions, such as IFNs. In a study on 
the regulation of the homeostasis of the human immune sys-
tem by its microbiome, Kim and colleagues evaluated the 
microbial composition of healthy nasal mucosa [87]. They 
subsequently evaluated whether nasal commensal microbes 
are involved in signaling as part of the defense mechanism 
against IVA [87]. They identified S. epidermidis as the most 
frequent microbial population. They found that S. epider-
midis cells collected from nasal mucosa of healthy subjects 
accelerated the elimination of IVA from the nasal epithelium 
via immune responses mediated by IFN-λ [87]. In addition, 
nasal S. epidermidis cells from humans prevented IVA infec-
tion in mice by promoting innate immune reactions mediated 
by IFN-λ in the nasal mucosa [87]. There have been reports 
of a crucial mechanistic association between susceptibility 
to various VIs and innate nasal immunity mediated by the 
microbiome.
Compositional and structural variations in the host res-
piratory microbiota arising from various environmental fac-
tors have been predicted, and the host respiratory microbi-
ome has been found to be important for immune protection 
[10, 151]. Therefore, an understanding of the composition 
of the respiratory mucosal microbiome and the substantial 
adverse effects of medications on these microbial commu-
nities is needed to develop novel methods for treating and 
preventing RIs. Nasal mucosa cells are crucial players in 
immunological resistance to infections of the respiratory 
system. They are responsible for the filtration of various 
respiratory microbial pathogens from normal inhalation to 
pressurized airflow. Various RVs confront host immunity 
primarily in the lower and upper respiratory epithelia [67, 
81]. Protection against various viral infections can be attrib-
uted to the innate immune mechanisms of the human nasal 
epithelium for counteracting invasions by respiratory viruses 
[87]. Therefore, researchers must focus on the involvement 
of nasal microbiota, particularly S. epidermidis strains, in 
mucosal innate immune defense strategies against viruses. 
In the respiratory tract, innate immunity contributes to anti-
viral immunity through secretion of IFNs [139, 144]. The 
activity of type 1 IFNs in the stimulation of antiviral innate 
and adaptive immune reactions has been studied extensively 
[136, 198]. IFN-λ is an important factor in antiviral reac-
tions against influenza viruses and rhinoviruses in human 
lungs [87]. It is also the prevailing IFN stimulated by IVA 
and is involved in the primary defense barrier against VIs in 
nasal epithelial cells [87]. Studies have focused on studying 
the host immune moderators involved in the production of 
IFN-λ cytokines in the nasal mucosal layer, suggesting that 
the nasal microbiota may control IFN-λ production [87]. 
Kim and colleagues demonstrated that S. epidermidis has 
potent antiviral activity in the nasal epithelium and that all 
antiviral reactions induced by this organism are mediated by 
IFN-λ, and not IFN-γ, IFN-β, or IFN-α [87].
Recent data have shown that commensal S. epidermidis 
can be sensed by Toll-like receptor 2 in the host nasal epi-
thelium. However, IFN-λ stimulated by S. epidermidis 
via signal transduction (ST) is associated with transcrip-
tion factors (TFs). IFN regulatory factor 3 (IRF3) and IFN 
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regulatory factor 7 (IRF7) are TFs that are associated with 
IFN-λ and IFN production by direct ST via the phospho-
rylation of IRF7 and IRF3 [32, 217]. While IRF3 is usually 
thought to be required for triggering of IFN transcription, 
a deficiency in IRF3 has been shown to have little effect on 
the expression of IFN [32]. In contrast, the absence of IRF7 
significantly reduces IFN production in the host airway epi-
thelium [32]. Kim and colleagues showed that S. epidermidis 
cells as nasal commensals can increase the phosphorylation 
of IRF7 relative to IRF3 and eventually stimulate immune 
responses related to IFN-λ in the host nasal epithelium [87]. 
However, they did not determine the molecular mechanism 
that prompted phosphorylation of IRF7 by S. epidermidis. 
It can be speculated that free molecules from S. epidermidis 
interact with IRF7 and prompt strong IFN-related antivi-
ral immune reactions in the airways. Comparative genomic 
studies can explain how innate immunity reactions are stim-
ulated to react with symbiotic commensals. These findings 
provide further information about how the nasal commensals 
enhance IFN-dependent innate immunity against IVA infec-
tions to protect the respiratory tract. These findings indicate 
that, as the prevailing nasal commensal in humans, S. epi-
dermidis improves protection against IVA infection in nasal 
epithelium via IRF-7-dependent production of IFN-λ and 
prevents IVA lung infection via the suppression of IVA rep-
lication in nasal mucosa. Therefore, intranasal inoculation 
with S. epidermidis might be an effective way of preventing 
viral respiratory infections through the stimulation of IFN-
λ-related innate immune reactions.
Most importantly, in a promising approach, research-
ers from Stanford University have started a clinical trial to 
investigate whether IFN-λ-treatment can help COVID-19 
patients and decrease transmission of virus, since IFN- λ 
appears to help control viral respiratory diseases such as 
influenza and SARS [121].
Dysbiosis of gut microbiota in COVID‑19 
patients
Dysbiosis, which is defined as a persistent imbalance of 
the microbiota, has been associated with several intestinal 
and extraintestinal diseases [11]. Studies have indicated an 
association between the pharyngeal microbiota and SARS-
CoV-2 infection [18]. According to these studies, the com-
position of the pharyngeal microbiota change with age, with 
older individuals having a less diverse microbial community 
[5]. This might contribute to the higher susceptibility of the 
aged to COVID-19, but more investigations are needed to 
confirm this. Dysbiosis can lead to an inflammatory milieu 
that can be exploited by SARS-CoV-2 [5]. It has been found 
that cytokines are elevated following COVID-9, possibly 
leading to a "cytokine storm," which can be more harmful 
than the virus itself [5, 209]. Recent studies have recog-
nized bacterial markers associated with sensitivity to SARS-
CoV-2 infection [59]. Based on the data from COVID-19 
subjects, a blood proteomic risk score (PRS) was designed to 
predict the progression and severity of SARS-CoV-2 disease 
[59]. It was found that Ruminococcus gnavus had a positive 
correlation with inflammation, while Clostridia spp. showed 
a negative correlation [59]. A strong association was also 
demonstrated between the severity of SARS-CoV-2 infection 
in the elderly and the bacteria mentioned above as well as 
the PRS. This study investigated a subgroup of 301 healthy 
individuals over three years [59]. Interestingly, microbiome 
modifications were indicated by the PRS, implying that dys-
biosis stimulated protein modifications [59].
The SARS-CoV-2 S glycoprotein binds to human ACE2 
[205], an enzyme that is expressed in esophageal and intes-
tinal epithelia as well as lung tissue, and this could con-
tribute to dysbiosis in the normal flora and gastrointestinal 
symptoms following SARS-CoV-2 infection [61, 76, 102]. 
Moreover, SARS-CoV-2 and its genetic material have been 
identified in the faeces of patients with diarrhea [95, 216, 
218] indicating the presence of SARS-CoV-2 in the human 
gastrointestinal tract and its possible transmission by the 
fecal-oral route.
The potential effects of probiotics 
on coronavirus infections and COVID‑19
Many studies are being undertaken to investigate the effects 
of probiotics on several coronavirus strains, as they are safe 
and capable of modulating immune reactions [83, 131]. 
In addition, a clinical study has described an imbalance 
in intestinal microbiota and significantly reduced levels of 
probiotics such as Lactobacillus and Bifidobacterium in 
COVID-19 cases, possibly facilitating secondary bacterial 
infections [206]. A recent study has demonstrated that por-
cine epidemic diarrhea virus (PEDV) can be inhibited using 
cell-free supernatants or live lactic acid bacteria [171]. In 
that study, using CPE reduction assays and qualitative immu-
nofluorescence, it was shown that probiotics could be useful 
in eliminating PEDV in a strain-specific manner [171]. In a 
different study, Lactobacillus casei was employed as a vehi-
cle for the DC-targeting peptide (DC-pep) along with the 
PEDV core neutralizing epitope (COE) antigen [196]. It was 
shown that a genetically modified Lactobacillus casei oral 
vaccine could induce the production of IgG (systemic) and 
SIgA antibody (mucosal) in a murine model [196]. Several 
other studies have employed various probiotics to present 
PEDV genes or antigens of interest [111, 114, 196, 197]. Liu 
et al. [111] showed that an altered Lactobacillus plantarum 
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strain had antiviral activity against coronavirus infections in 
a porcine intestinal epithelial cell line.
The sequencing of microbiota in COVID-19 patients has 
shown a significant decrease in bifidobacteria and lactoba-
cilli as the prevailing symbiotic bacteria and an increase in 
the number of opportunistic bacteria such as Corynebacte-
rium or Ruthenibacterium [51]. The immune system in the 
lung can be affected by intestinal dysbiosis, which therefore 
might aggravate respiratory distresses caused by COVID-19 
[23]. In this regard, oral bacteriotherapy might be useful. 
Some strains of the genera Lactobacilli and Bifidobacterium 
have a protective function against IV, RVs, RSV, adenovirus, 
and pneumovirus [20, 115]. As no definitive treatments or 
guidelines have been established for COVID-19, d’Ettorre 
et al. [33] investigated the efficacy of oral bacteriotherapy 
as an additional curative option to prevent the progress of 
COVID-19. Their bacterial formulation included Streptococ-
cus thermophilus DSM 32345, L. acidophilus DSM 32241, 
Lactobacillus helveticus DSM 32242, Lactobacillus paraca-
sei DSM 32243, Lactobacillus Plantarum DSM 32244, Lac-
tobacillus brevis DSM 27961, Bifidobacterium lactis DSM 
32246, Bifidobacterium lactis DSM 32247 [33]. They inves-
tigated two groups: 1) patients treated with hydroxychlo-
roquine, tocilizumab, and antimicrobials alone or in com-
bination and 2) patients treated with oral bacteriotherapy 
plus a conventional medication regimen [33]. Their results 
showed that patients who also received bacteriotherapy had 
a higher survival rate and a lower need for intensive resusci-
tation [33]. The predicted risk of developing respiratory col-
lapse due to COVID-19 infection was lower in patients who 
received oral bacteriotherapy [33]. When other manifesta-
tions of COVID-19 were considered, including asthenia, 
pyrexia, cough, dyspnea, diarrhea, and myalgia, a notable 
improvement was already seen as early as 24–48 h after the 
start of the bacteriotherapy [33]. The authors hypothesized 
that in COVID-19 patients, bacterial compounds with the 
“proper” immunological and biochemical profiles could 
promote host immunity. The antioxidant pathway nuclear 
factor erythroid 2p45-related factor 2 (Nrf2) and heme oxy-
genase-1 (HO-1) were elevated in response to the bacterial 
formulation [21]. These molecules can modulate oxidative 
stress, thereby exerting antiviral functions [33]. Antiviral 
activity of Nrf2 and HO-1 has been observed against human 
immunodeficiency virus (HIV), IV, RSV, Ebola virus, and 
dengue virus [45, 48, 69, 72, 182]. Interestingly, the benefi-
cial characteristics of HO-1 include activity against respira-
tory viruses.
COVID-19 is a severe pulmonary disease, with manifes-
tations including fever, cough, breathing difficulty, fatigue, 
muscle pain, diarrhea, sore throat, and abdominal disorders 
[137, 170]. While most patients experience mild symptoms, 
some experience viral pneumonia and multiple organ failure 
[211]. Until now, COVID-19 prevention has been based on 
maintaining good hygiene by washing hands and avoiding 
contact with infected individuals [138], but reinforcing the 
immune system might also be helpful (Fig. 2) [173]. In the 
human body, trillions of beneficial bacteria live in homeo-
stasis to help their host to digest food, produce precursors for 
neurotransmitters, and enhance the immune response against 
pathogens [12]. It has been found that microbiota dysbiosis 
is associated with several disorders [42]. Probiotic bacteria 
can interact with microbiota to reinforce the immune system 
and prompt immune reactions [203, 208]. Some probiotics 
have been found to prevent bacterial and viral infections or 
decrease their duration. Lactobacillus reuteri DSM 17938 
has been shown to be protective against RI signs and gas-
trointestinal disorders such as diarrhea in children [2, 65, 
200]. It has also been found that probiotics can be useful in 
enhancing vaccine immunogenicity, increasing the rate of 
seroconversion and seroprotection in adults immunized with 
flu vaccines [99]. Additionally, probiotics, together with 
vitamins, can enhance the immune system. For example, 
vitamin D can modulate immune reactions [7].
Although its pathophysiological mechanism has not been 
entirely elucidated, COVID-19 is known to affect the lungs 
and airways [210]. However, since immunological mecha-
nisms play an important role in the course of the disease, 
a novel therapeutic approach involving probiotic bacterial 
strains might be promising because of their involvement in 
immune modulation [120, 204, 210]. In this regard, inter-
leukin-17 is a pro-inflammatory cytokine with a crucial 
role in the adaptive immune system, and it is also a potent 
inducer of endoplasmic reticulum stress autophagy through 
inositol-requiring enzyme 1 [17, 88]. By blocking this inter-
leukin, autophagy mediated by endoplasmic reticulum stress 
and inflammation can be prevented [60, 88]. Interestingly, 
Bifidobacterium strains have an inhibitory effect on inter-
leukin-17 [17]. Consequently, administration of high doses 
of Bifidobacterium strains such as B. animalis subsp. lacti 
BB-12 as well as lipopolysaccharides from this strain [164, 
174] could be used as a therapeutic and preventive approach 
in COVID-19 patients, particularly in those with gastroin-
testinal symptoms.
A biotechnology company (Biosearch Life) found that 
Lactobacillus coryniformis CECT5711 K8 can decrease 
virus transmission during respiratory infections in older 
adults. Accordingly, they assessed the efficacy of K8 in 
diminishing the frequency or severity of SARS-CoV-2 
in a clinical trial [80]. In a study by Xu et al. [207], some 
COVID-19 patients develop intestinal microbial dysbiosis 
with lowered levels of probiotics such as Bifidobacterium 
and Lactobacillus. Therefore, gastrointestinal health should 
be assessed in all COVID-19 patients. The application of 
probiotics and nutritional support has been shown to main-
tain intestinal microbiota equilibrium and decrease the haz-
ard of secondary bacterial infections [207]. Recent work by 
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Yoon et al. showed that Lactobacillus gasseri could decrease 
the spread of SARS-CoV-2 by inhibiting purine as the viral 
energy source, as this source is required for mutation of the 
virus; hence, it can be expected that probiotic bacteria can 
be considered as potent supplements to suppress the spread 
of COVID-19 by inhibiting purine activity [157]. However, 
the reinforcement of immune reactions by safe strategies, 
such as maintaining a normal gut microbial heterogeneity 
and preventing colonic dysbiosis in the aged, children, and 
the general community, is probably beneficial for recovery 
from COVID-19. A balanced diet with probiotics and vita-
min supplementation can help to reinforce the immune sys-
tem against SARS-CoV-2.
Several metabolites derived from Lactobacillus plan-
tarum, including plantaricin, lactic acid, acetic acid, and 
gamma-aminobutyric acid, can boost the immune response 
against viral pathogens [4]. In order to initiate infection, the 
virus must recognize its receptor. Lie et al. [103] suggested 
that the binding affinity of SARS-CoV-2 for hACE2 is linked 
to the rate of viral transmission and the severity of disease. 
SARS-CoV-2 enters host cells through S glycoprotein homo-
trimers on the viral surface [181, 191]. The S glycoprotein 
binds human ACE2 receptors with high affinity [189]. 
Anwar et al. [6] targeted both the S glycoprotein and ACE2 
using a plantaricin metabolite and showed that plantaricin, 
via binding to the receptor binding domain (RBD), prevents 
the entry of SARS-CoV-2. They also targeted the viral RNA-
dependent RNA polymerase (RdRp), which is required for 
viral replication. Anwar et al. [6] chose four metabolites 
produced by Lactobacillus plantarum (metabolites derived 
from plantaricin, including plantaricin BN, plantaricin JLA-
9, plantaricin W, and plantaricin D) to design antiviral drugs 
that, based on computer simulations, showed the potential to 
be employed as probiotics to delay, prevent, and eliminate 
SARS-CoV-2 in individuals by hindrance or inactivation of 
RdRp, prevention of the emergence of newly budded virus 
Fig. 2  The antiviral effects of probiotics during SARS-CoV-2 infection
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progeny, inhibition of the RBD fragment of the S protein, or 
interference with other proteins such as the ACE2 receptor. 
They used computational analysis to predict the antiviral 
activity of plantaricin compounds through several different 
mechanisms. Metabolic products of Lactobacillus plan-
tarum inhibit viral entry by interacting with RdRp, RBD, 
and ACE2 [1, 6]. Blocking the S protein, a major structural 
protein with a pivotal function in the life cycle of SARS-
CoV-2, could be one of the most promising strategies [6]. 
This was confirmed by a molecular model that established 
the durability of the networks of plantaricin w and SARS-
CoV-2 (RdRp, RBD, and ACE2 receptor) [6]. Computa-
tional and molecular models can accurately identify drugs 
that can be repurposed without requiring clinical trials. 
Moreover, it would be challenging to discover a medication 
that has a more favorable protection profile or a lower cost 
than macrolides. The use of plantaricin metabolites under 
proper medical supervision should be considered as a tem-
porary measure until a definite antiviral drug is discovered 
for COVID-19.
A promising probiotic‑based oral candidate 
vaccine against SARS‑CoV‑2
Several vaccines have been developed against SARS-CoV-2, 
and others are undergoing clinical trials [54, 192, 213]. 
Injected vaccines are costly and require expert administra-
tion, whereas, oral vaccines are more affordable, simple to 
store, easy to administer, and bio-friendly [94, 162, 166]. 
It has also been shown that oral vaccines can induce the 
robust production of specific IgG and IgA as well asTh1 
and Th17 responses, thereby inhibiting viral replication in 
the respiratory tract and intestinal mucosa [109, 132, 195]. 
Thus, an efficient oral vaccine for SARS-CoV-2 would be 
of great benefit.
Lactic acid bacteria are potentially suitable bacterial vec-
tors for oral DNA and protein delivery. They are frequently 
present in the human intestine and are beneficial in several 
gastro-intestinal and inflammatory diseases [43, 77, 159, 
163, 168, 172]. L. plantarum is generally known as a probi-
otic that can be employed in food, vaccines, and medication 
[9, 112, 153–156, 165]. Therefore, Wang et al. [194] devel-
oped an L. plantarum expression system for SARS-CoV-2 
S protein production. By optimizing the codon usage of the 
S gene, the S protein was efficiently presented on the bacte-
rial surface, leading to the generation of many misfolded 
peptide chains. This protein showed strong reactivity with 
an anti-HA-tagged rabbit polyclonal antibody and SARS-
Cov-2-S-protein-specific monoclonal antibodies [194]. The 
stability of the immunogenic protein is crucial for oral vac-
cines. Therefore, they examined the stability of the S pro-
tein presented on the bacterial surface and found that it was 
resistant to heat and low pH. The expression level of this 
protein was elevated following exposure to 0.2% bile salt, 
implying that the recombinant form of L. plantarum Lp18:S 
could be applied as an oral vaccine for COVID-19 [194].
Conclusion
SARS-CoV-2 is a newly emerging pathogen, and researchers 
are still in the early stage of understanding how this virus 
acts and the mechanisms by which it induces an immune 
response. Although the advantages of drugs and vaccines for 
the treatment and prevention of VIs have been demonstrated, 
their efficiency can be limited by changes that occur in viral 
populations, making it challenging to apply an entirely 
practical approach to prevent viral infections. However, the 
administration of probiotics can be beneficial in prevent-
ing VRIs, including COVID-19, and probiotic therapy may 
be considered as an alternative for the amelioration and/or 
prevention of COVID-19 disease. Overall, the application of 
probiotic bacteria against COVID-19 appears to be promis-
ing, both in terms of vaccination and treatment.
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